



ATTORNEY'S DOCKET NO. L0461/7066

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lethe et al.  
Serial No: 09/341,829  
Filed: October 18, 1999  
For: LAGE-1 TUMOR ASSOCIATED NUCLEIC ACIDS  
Examiner: M. Davis  
Art Unit: 1642


RECEIVED

FEB 02 2001

TECH CENTER 1600/2900

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to the Commissioner for Patents, Washington, D.C. 20231, on the 19th day of January, 2001.

  
Monica E. Zombori

Commissioner for Patents  
Washington, DC 20231

**STATEMENT PURSUANT TO 37 CFR 1.821(f) AND 37 CFR 1.825 (a) and (b)**

This statement is made pursuant to 37 CFR 1.821 (f), and 37 CFR 1.825 (a) and (b). Applicants submit herewith a substitute copy of the written sequence listing and a computer readable diskette to comply with the sequence requirements.

Applicants' attorney states that the information recorded in computer readable form is identical to the written sequence listing and that neither the computer readable form nor the written sequence listing contain new matter.

Respectfully submitted,

  
John R. Van Amsterdam, Reg. No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210-2211  
(617)720-3500

Docket No. L0461/7066  
Dated: January 19, 2001  
**X01/19/01**

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

☒ 1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

☒ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

☐ 7.

Other: \_\_\_\_\_

**Applicant must provide:**

☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.